We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.71%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$168M
AUM Growth
-$5.13M
Cap. Flow
+$3.65M
Cap. Flow %
2.17%
Top 10 Hldgs %
74.37%
Holding
57
New
9
Increased
8
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.3M
2
CGEM icon
Cullinan Oncology
CGEM
+$2.44M
3
NKTR icon
Nektar Therapeutics
NKTR
+$1.91M
4
ELTX icon
Elicio Therapeutics
ELTX
+$1.17M
5
ALKS icon
Alkermes
ALKS
+$716K

Top Sells

Rank Stock Value
1
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$5.4M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$2.97M
3
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$763K
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$384K
5
STOK icon
Stoke Therapeutics
STOK
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 96.34%
2 Energy 1.49%
3 Consumer Staples 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$50.1M 29.76%
794,186
-200
-0% -$12.4K
BDSX icon
2
Biodesix
BDSX
$209M
$22.4M 13.32%
55,248
-6
-0% -$2.68K
AXDX
3
DELISTED
Accelerate Diagnostics
AXDX
$18.4M 10.92%
221,333
+1,953
+0.9% +$198K
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$7.8M 4.63%
80,200
– –
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$7.5M 4.45%
58,644
– –
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.38B
$4.57M 2.71%
177,000
+75,000
+74% +$3.3M
FHTX icon
7
Foghorn Therapeutics
FHTX
$305M
$4.14M 2.46%
314,143
– –
ALBO
8
DELISTED
Albireo Pharma Inc
ALBO
$3.91M 2.32%
111,000
+19,000
+21% +$701K
BIIB icon
9
Biogen
BIIB
$30.4B
$3.38M 2.01%
12,100
– –
UTHR icon
10
United Therapeutics
UTHR
$22.7B
$3.01M 1.79%
18,000
– –
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$2.53M 1.5%
18,672
– –
CGEM icon
12
Cullinan Oncology
CGEM
$1.09B
$2.5M 1.49%
+60,114
New +$2.44M
KPTI icon
13
Karyopharm Therapeutics
KPTI
$216M
$2.42M 1.44%
15,333
+2,800
+22% +$590K
BLUE
14
DELISTED
bluebird bio
BLUE
$2.28M 1.35%
5,829
+1,043
+22% +$514K
AMRN
15
Amarin Corp
AMRN
$292M
$1.86M 1.11%
15,000
– –
NKTR icon
16
Nektar Therapeutics
NKTR
$2.31B
$1.84M 1.09%
+6,133
New +$1.91M
MASI
17
DELISTED
Masimo
MASI
$1.84M 1.09%
8,000
– –
IMGN
18
DELISTED
Immunogen Inc
IMGN
$1.54M 0.91%
190,000
– –
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
$1.54M 0.91%
30,000
– –
ARNA
20
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.53M 0.91%
22,000
– –
BIOR
21
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$1.28M 0.76%
1,080
+80
+8% +$110K
HROW icon
22
Harrow
HROW
$1.74B
$1.22M 0.72%
180,000
– –
VNDA icon
23
Vanda Pharmaceuticals
VNDA
$327M
$1.2M 0.71%
80,000
– –
CORT icon
24
Corcept Therapeutics
CORT
$9.72B
$1.19M 0.71%
50,000
– –
SLNO
25
DELISTED
Soleno Therapeutics
SLNO
$1.1M 0.66%
58,460
+3,333
+6% +$107K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Birchview Capital held 57 positions worth $168M, down 3% from $174M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Birchview Capital's Q1 2021 filing shows 9 new, 8 increased, 4 reduced and 3 closed positions. Its largest new stake was Cullinan Oncology: 60,114 shares worth $2.5M. The largest sale was Aspira Women's Health Inc. Common Stock, an estimated $5.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2021 buy was Cullinan Oncology: 60,114 shares worth $2.5M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q1 2021, an estimated $3.3M increase.
  • Birchview Capital's biggest Q1 2021 reduction was Aspira Women's Health Inc. Common Stock, cutting an estimated $5.4M.
  • Birchview Capital fully exited Oxford Immunotec Global PLC Ordinary Shares in Q1 2021, selling an estimated $2.97M.
  • Birchview Capital's ten largest holdings make up 74% of its $168M portfolio in Q1 2021.
  • Birchview Capital opened 9 new positions and closed 3 in Q1 2021.
  • Birchview Capital's portfolio value fell 3% quarter-over-quarter to $168M.

Based on Birchview Capital's 13F filing for Q1 2021, filed 14 May 2021.